Invariance mapping of the complete HBV genome and testing of MRE11 repair nuclease toward the improvement of crispr/CAS therapy for hepatitis b

The Department of the Army Medical Command awarded Invvax, Inc. a $1,878,970 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to support research titled "Invariance Mapping of the Complete HBV Genome and Testing of MRE11 Repair Nuclease Toward the Improvement of CRISPR/Cas Therapy for Hepatitis B." The period of performance is from September 1, 2022 to August 31, 2026.

Under this award, Invvax will conduct research to map the complete genome of the hepatitis B virus and test the MRE11 repair nuclease to improve CRISPR/Cas gene therapy approaches for treating hepatitis B. The goal is to transform treatment for military service members and the public by investigating medical solutions applicable to the battlefield and developing innovative therapies. The research funded under this award aims to advance biomedical knowledge and technology to improve healthcare outcomes for those suffering from hepatitis B.